Skip to main content
. 2019 May 6;20(6):e47074. doi: 10.15252/embr.201847074

Figure 1. IMP1 is upregulated in patients with Crohn's disease and ulcerative colitis.

Figure 1

  1. qPCR analysis for IMP1 expression in colon biopsy samples from adult ulcerative colitis (UC) and Crohn's disease (CD) patients. IMP1 expression is > 5‐fold higher in UC (6.554 ± 2.609, n = 6; P‐value = 0.0302) and CD samples (5.314 ± 1.807, n = 8; P‐value = 0.0343) as compared to control samples (1 ± 0.1245, n = 6).
  2. Representative immunohistochemistry demonstrating IMP1 expression in colon biopsy samples from CD patients and normal adults (Scale bars = 500 μm).
  3. Differential gene expression analysis of pediatric ileal CD patient samples (n = 180) shows increased (> 4‐fold) IMP1 expression as compared to non‐inflammatory bowel disease (IBD) pediatric samples (n = 43).
  4. Experiment schematic. Mice were given either 3% or 5% dextran sodium sulfate (DSS) in drinking water for 5 days followed by 4 days of recovery.
  5. With 3% DSS, mice with Imp1 deletion [Imp1 ΔIEC (n = 8)] lost significantly less weight compared to controls (Imp1 WT (n = 18); P‐value = 0.0259 at day 6).
  6. With 5% DSS, Imp1 ΔIEC mice began to regain weight at day 9 compared to controls (Imp1 WT (n = 22) and Imp1 ΔIEC (n = 16; P‐value = 0.0104).
  7. Imp1 ΔIEC mice show significantly less total colitis (11.14 ± 1.933, n = 7; scored blinded by a pathologist) as compared to Imp1 WT mice (17.75 ± 2.144, n = 8) after 5% DSS (P‐value = 0.0415).
  8. Imp1 ΔIEC mice show significantly less epithelial loss (5.286 ± 0.865, n = 7) as compared to Imp1 WT mice (9.375 ± 1.375, n = 8) after 5% DSS (P‐value = 0.0303).
Data information: All data are expressed as mean ± SEM. *P < 0.05; **P < 0.01 by unpaired two‐tailed t‐test (for DSS weights, significance was determined using the Mann–Whitney test).